USANA Health Sciences, Inc. Q3 2026 Earnings Call Summary
The 2026 outlook for Rise Wellness is dependent on the timing of retail orders currently scheduled for the fourth quarter; a ...
Model output · Signal date 2026-11-06
Usana Health Sciences Inc (USNA) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
28.0%
Spearman, 357 dates
Market Cap
$256M
small-cap · #8 of 28 peers
Summary
Usana Health Sciences Inc (USNA) stock forecast summary
Our AI scores Usana Health Sciences Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Usana Health Sciences Inc is a small-cap company with a market capitalization of $256M. It ranks number 8 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast. Its Gross Margin of 77.5% is the highest of the 21 peers that report one.
For USNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 28.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, USNA included.
Price
USNA price chart and AI forecast
Cross-section · 2026-11-06
How USNA ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-07-04
Usana Health Sciences Inc (USNA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | USNA | Rank |
|---|---|---|
| Market Cap | $256M | 8/28 |
| P/B Ratio | 0.49x | 10/13 |
| EPS | $-1.10 | – |
| Book Value/Share | $28.49 | – |
| Revenue/Share | $49.43 | – |
| FCF/Share | $0.86 | – |
Profitability & Margins
| Metric | USNA | Rank |
|---|---|---|
| ROE | -4.2% | 3/15 |
| ROA | -3.1% | 4/21 |
| ROIC | -0.2% | 7/18 |
| Gross Margin | 77.5% | 1/21 |
| Operating Margin | -0.1% | 7/23 |
| Net Margin | -2.4% | 4/19 |
| EBT Margin | 0.3% | 7/23 |
| Tax Rate | 1253.3% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | USNA | Rank |
|---|---|---|
| Current Ratio | 2.66x | 7/25 |
| Quick Ratio | 1.84x | 7/23 |
| D/E Ratio | 0.25x | 13/16 |
| Financial Leverage | 1.34x | 12/16 |
| Interest Coverage | -86.6x | 21/21 |
| Working Capital | $175M | 7/25 |
Cash Flow
| Metric | USNA | Rank |
|---|---|---|
| Operating Cash Flow | $28M | 4/27 |
| Free Cash Flow | $16M | 4/12 |
| Capital Spending | -$12M | 7/12 |
| OCF Growth YoY | -57.5% | 6/10 |
| FCF Growth YoY | -75.7% | 5/5 |
| FCF/Sales | 1.7% | 7/12 |
| CapEx/Sales | 1.3% | 8/12 |
Operational Efficiency
| Metric | USNA | Rank |
|---|---|---|
| Asset Turnover | 1.30x | 4/15 |
| Receivables Turnover | 273.7x | 2/14 |
| Inventory Turnover | 2.4x | 12/19 |
| Fixed Assets Turnover | 9.7x | 7/16 |
| Days Sales Outstanding | 1 days | 13/14 |
| Days Inventory | 153 days | 7/18 |
| Payables Period | 27 days | 16/17 |
| Cash Conversion Cycle | 127 days | 4/12 |
Income Statement
| Metric | USNA | Rank |
|---|---|---|
| Total Revenue | $913M | 4/17 |
| Operating Income | -$1M | 10/26 |
| Net Income | -$22M | 13/21 |
| SG&A Expense | $335M | 2/16 |
| Cost of Goods Sold | $206M | 4/22 |
Dividend & Shareholder Information
| Metric | USNA | Rank |
|---|---|---|
| Shares Outstanding | 18M | – |
| Net Income Growth | -155.0% | 4/5 |
| EPS Growth | -244.7% | 6/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $281M | 40.0% of assets |
| Cash & Short-term Investments | $169M | 24.0% of assets |
| Accounts Receivable | $3M | 0.5% of assets |
| Inventory | $86M | 12.3% of assets |
| Total Liabilities | $132M | 18.8% of assets |
| Short-term Debt | $90M | 12.8% of assets |
Quarterly Financial Reports
USNA quarterly financials and insider trading
Industry Peers · Medicinal Chemicals & Botanical Products
Usana Health Sciences Inc (USNA) industry peers
Companies classified under the same SEC industry code as Usana Health Sciences Inc (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| USNA Usana Health Sciences Inc | $256M | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Where USNA sits on the market map
Life Sciences · Medicinal Chemicals & Botanical Products
News
Usana Health Sciences Inc (USNA) stock news
Usana Health Sciences Inc (USNA) Q2 2025 Earnings Report Preview: What to Look For
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
USANA Health Sciences, Inc. (USNA) Q3 2025 Earnings Call Transcript
Greetings, and welcome to the USANA Health Sciences third quarter earnings call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your ...
FAQ
Usana Health Sciences Inc (USNA) stock forecast FAQ
What is the Usana Health Sciences Inc (USNA) stock forecast?
Our AI scores Usana Health Sciences Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Usana Health Sciences Inc stock predictions?
For USNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 28.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Usana Health Sciences Inc forecasts updated?
Usana Health Sciences Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Usana Health Sciences Inc's industry peers?
30 issuers in our coverage, USNA included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.